Luis Echarte, MD
Pulmonary Disease · Aventura, FLNPI 1043232028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,367 and has fallen 61.5% since, to $526 in 2025.
Across 209 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1000
- GSK$846
- Regeneron Healthcare Solutions, Inc.$297
- Mylan Specialty L.p.$274
- Boehringer Ingelheim$244
- Sanofi$234
- plus $1K from 26 others
Across 53 payments — averaging $4081.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$113K
- Pfizer$48K
- Genentech, Inc.$41K
- Sanofi US Services Inc.$14K
What the payments were for
- Food & beverage$4,164100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $1,000 |
| GSK | 60 | $846 |
| Regeneron Healthcare Solutions, Inc. | 11 | $297 |
| Mylan Specialty L.p. | 11 | $274 |
| Boehringer Ingelheim | 9 | $244 |
| Sanofi | 11 | $234 |
| Philips North America LLC | 7 | $185 |
| Insmed, Inc. | 6 | $157 |
| Baxter Healthcare | 6 | $152 |
| Mallinckrodt Hospital Products Inc. | 4 | $89 |
| Pfizer | 4 | $82 |
| Genentech USA, Inc. | 4 | $73 |
| United Therapeutics Corporation | 6 | $72 |
| Circassia Inc. | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Verona Pharma, Inc. | 2 | $48 |
| Jazz Pharmaceuticals Inc. | 1 | $40 |
| Electromed, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Viatris Specialty LLC | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Resmed Corp | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$119
How this compares
$4,184 in reported general payments places this provider in the 55th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 89 | $73,498 |
| EliquisApixaban | 57 | $63,237 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $55,844 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $41,480 |
| MounjaroTirzepatide | 30 | $30,530 |
| OzempicSemaglutide | 14 | $27,562 |
| JardianceEmpagliflozin | 24 | $26,867 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $23,199 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $22,794 |
| LinzessLinaclotide | 18 | $21,899 |
| XareltoRivaroxaban | 27 | $19,229 |
| Spiriva RespimatTiotropium Bromide | 29 | $17,423 |
| Repatha SureclickEvolocumab | 15 | $13,675 |
| FarxigaDapagliflozin Propanediol | 12 | $11,401 |
| VascepaIcosapent Ethyl | 13 | $10,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $1,000 | $107,692170 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $846 | $101,498149 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $244 | $67,48987 claims |
| PfizerEliquis | $82 | $63,23757 claims |
| Lilly USA, LLCMounjaro | $25 | $30,53030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Aventura
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.